Reported Earnings • Aug 02
Third quarter 2024 earnings released: EPS: US$1.68 (vs US$1.37 in 3Q 2023) Third quarter 2024 results: EPS: US$1.68 (up from US$1.37 in 3Q 2023). Revenue: US$4.99b (up 2.3% from 3Q 2023). Net income: US$487.0m (up 24% from 3Q 2023). Profit margin: 9.8% (up from 8.0% in 3Q 2023). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Medical Equipment industry in Europe. Tillkännagivande • Aug 01
Becton, Dickinson and Company Updates Earnings Guidance for the Year 2024 Becton, Dickinson and Company updated earnings guidance for the year 2024. For the year, the company expects GAAP Revenues in the range of $20.1 billion compared to the previous guidance of $20.1 to $20.3 billion provided earlier and expects GAAP Revenue Growth of 3.7%. Organic Revenue Growth of 5.0% to 5.25% compared to the previous guidance of 5.5% to 6.25% provided earlier. Tillkännagivande • Jul 24
Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2024 The Board of Directors of BD (Becton, Dickinson and Company) announced it has declared a quarterly dividend of $0.95 per common share, payable on September 30, 2024 to holders of record on September 9, 2024. The indicated annual dividend rate is $3.80 per share. Tillkännagivande • Jul 04
Becton, Dickinson and Company to Report Q3, 2024 Results on Aug 01, 2024 Becton, Dickinson and Company announced that they will report Q3, 2024 results at 6:30 AM, US Eastern Standard Time on Aug 01, 2024 Tillkännagivande • Jun 26
BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research Tool BD (Becton, Dickinson and Company) announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases. Researchers worldwide are currently using innovative approaches to study multiple aspects of health and disease at a single-cell level. In the ever-evolving field of biological research, the newly launched BD Rhapsody Single Cell ATAC-Seq (assay for transposase-accessible chromatin using next-generation sequencing) Assay enables scientists to perform single-cell analysis of the epigenome – the set of chemical marks, or epigenetic changes, on the DNA in a single cell that holds critical clues about mechanisms of disease. Adding an epigenomic layer-view will play a crucial role in helping researchers track and understand how environmental factors impact the DNA and corresponding cell function. By gaining such knowledge about DNA, scientists can deepen their understanding of how diseases progress and apply those learnings to develop effective therapies. Commercially available globally June 26, 2024, the BD Rhapsody ATAC-Seq Assay, BD Rhapsody TCR/BCR Next Multiomic Assay and BD Rhapsody Intracellular CITE-seq Assay are designed to be used on the BD Rhapsody Single-Cell Analysis System – a gentle, microwell-based instrument for conducting single cell research. The BD single-cell multiomics portfolio is available for purchase from BD representatives, or in some regions, through its ecommerce portal. Tillkännagivande • Jun 05
Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion. Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion on June 3, 2024. BD expects to fund the all-cash transaction with approximately $1 billion of cash and $3.2 billion of new debt. Upon closing, Critical Care will operate as a separate business unit within BD’s Medical segment to align with its smart connected care approach, and it will maintain its presence in Irvine, Calif. Katie Szyman, who has served as corporate vice president of Critical Care since 2015, will lead the new business unit within BD, reporting to Mike Garrison, executive vice president and president of the BD Medical segment.
The transaction is subject to customary regulatory reviews, the receipt of required antitrust and foreign investment approvals and closing conditions. The transaction is expected to close before the end of the 2024.
At closing, BD is expected to have net leverage of approximately 3x and expects to de-lever to its 2.5x long-term net leverage target within 12 to 18 months of closing, primarily by deploying its free cash flows to debt repayment. The transaction meets all of BD’s rigorous investment criteria on growth, profitability and returns. It is expected to be immediately accretive to all key financial measures, including BD’s revenue growth, adjusted gross and operating margins, and adjusted earnings per share. Critical Care’s long-term financial profile is also expected to deliver durable revenue growth of approximately 6% to 7%, with year-one adjusted gross margin of at least 60% and adjusted operating margins of at least 25% that increase over time. Consistent with the company’s BD 2025 strategy, growth-enhancing and value-creating tuck-in M&A continues to be a key part of BD’s targeted financial profile.
Perella Weinberg Partners and Citi acted as financial advisers, and Ropes & Gray, LLP acted as legal counsel to BD. Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC acted as financial advisors, and Skadden Arps acted as legal counsel to Edwards. Tillkännagivande • May 03
Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2024 Becton, Dickinson and Company revised earnings guidance for the fiscal year 2024. For the year, company expects revenues to be in the range of approximately $20.1 billion to $20.3 billion compared to previous guidance of $20.2 billion to $20.4 billion. The company now expects organic revenue growth to be 5.5% to 6.25% compared to previous guidance of 5.5% to 6.25%. Reported Earnings • May 02
Second quarter 2024 earnings released: EPS: US$1.86 (vs US$1.54 in 2Q 2023) Second quarter 2024 results: EPS: US$1.86 (up from US$1.54 in 2Q 2023). Revenue: US$5.05b (up 4.6% from 2Q 2023). Net income: US$537.0m (up 23% from 2Q 2023). Profit margin: 11% (up from 9.1% in 2Q 2023). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Medical Equipment industry in Europe. Tillkännagivande • May 01
Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 28, 2024 The Board of Directors of BD (Becton, Dickinson and Company) announced it has declared a quarterly dividend of $0.95 per common share, payable on June 28, 2024 to holders of record on June 10, 2024. The indicated annual dividend rate is $3.80 per share. Tillkännagivande • Apr 27
Becton, Dickinson and Company (NYSE:BDX) acquired FlowJo LLC. Becton, Dickinson and Company (NYSE:BDX) acquired FlowJo LLC recently. Tillkännagivande • Mar 06
Becton, Dickinson and Company Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease Becton, Dickinson and Company announced the enrollment of the first patient in the investigational device exemption (IDE) study, AGILITY, which will assess the safety and effectiveness of the BD Vascular Covered Stent for the treatment of Peripheral Arterial Disease (PAD). The investigational Vascular Covered Stent is a self-expanding, low profile, polytetrafluoroethylene encapsulated nitinol implant. It is deployed from a delivery system that provides controlled stent release. According to BD, the global, prospective, multi-center, single-arm, non-randomized AGILITY clinical study will include 315 patients at up to 40 clinical study sites across the United States, Europe, Australia and New Zealand. Follow-up for all treated patients will be performed at various points after treatment starting at one month and ending at 36 months. PAD affects more than 18 million Americans and more than 236 million people worldwide. It is a potentially debilitating disease that can lead to increased risk of cardiovascular complications and limb amputation. A healthy diet, exercise and cessation of smoking can help mitigate the development of PAD, which includes the formation of atherosclerosis and blood clots in arteries in the legs. Minimally invasive techniques using devices such as angioplasty balloons, drug-coated balloons, atherectomy and covered stents can be used to increase blood flow through the diseased areas. The first patient in the AGILITY study was enrolled at Trinity Medical Center in Bettendorf, Iowa by Dr. Nicolas Shammas, Interventional Cardiologist, Cardiovascular Medicine, PLLC. Tillkännagivande • Feb 29
Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024 BD (Becton, Dickinson and Company) announced that Dave Hickey has informed the company of his intent to retire from BD, effective July 1, 2024. Hickey is currently executive vice president and president of the Life Sciences segment for BD, a position he has held since January 2021. Prior to his current role, Hickey was president of Integrated Diagnostic Solutions from 2019 to 2021, and president of Diagnostic Systems prior to that. Before joining BD in 2014, Hickey served in a range of executive leadership positions at Siemens Healthcare. BD intends to name a successor to Hickey prior to his retirement date. Reported Earnings • Feb 01
First quarter 2024 earnings released: EPS: US$0.97 (vs US$1.71 in 1Q 2023) First quarter 2024 results: EPS: US$0.97 (down from US$1.71 in 1Q 2023). Revenue: US$4.71b (up 2.6% from 1Q 2023). Net income: US$281.0m (down 42% from 1Q 2023). Profit margin: 6.0% (down from 11% in 1Q 2023). Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Europe. Tillkännagivande • Feb 01
Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year of 2024 Becton, Dickinson and Company raised earnings guidance for the fiscal year of 2024. For the year, company expects revenues to be in the range of approximately $20.2 billion to $20.4 billion compared to $20.1 billion to $20.3 billion previously and Organic revenue growth is now expected to be 5.5% to 6.25% compared to 5.25% to 6.25% previously. Tillkännagivande • Jan 24
Becton, Dickinson and Company Declares Quarterly Dividend, Payable on March 29, 2024 The Board of Directors of Becton, Dickinson and Company announced it has declared a quarterly dividend of $0.95 per common share, payable on March 29, 2024 to holders of record on March 8, 2024. The indicated annual dividend rate is $3.80 per share. Tillkännagivande • Jan 05
Becton, Dickinson and Company to Report Q1, 2024 Results on Feb 01, 2024 Becton, Dickinson and Company announced that they will report Q1, 2024 results at 6:30 AM, US Eastern Standard Time on Feb 01, 2024 Tillkännagivande • Dec 16
Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024 Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024, at 13:00 US Eastern Standard Time. Tillkännagivande • Dec 08
BD Receives FDA 510(K) Clearance for Potentially Transformative Fingertip Blood Collection Device BD announced it has received 510(k) clearances from the U.S. Federal Drug Administration (FDA) for a novel blood collection device that obtains blood samples from a fingerstick that produce lab-quality results for some of the most commonly ordered blood tests. The BD MiniDraw™ Capillary Blood Collection System is less invasive than a traditional venous blood draw by using capillary blood collected from a patient's finger by a trained healthcare worker, without the need for a phlebotomist to collect blood from a vein. The innovative design provides a sample that produces lab-quality blood test results from a fraction of the volume of traditional venous collections. It is less invasive than traditional venous blood collection methods and more convenient for the patient by expanding access to blood collection to new locations, including retail pharmacies. The device may provide a better patient experience and has the potential to transform diagnostic testing. The 510(k) clearances include low-volume blood collection for a lipid panel, selected chemistry tests, and hemoglobin and hematocrit (H&H) testing. These tests are among the most commonly ordered lab tests and can be used to diagnose and monitor a variety of chronic conditions from hypertension to high cholesterol. BD plans to expand blood tests enabled by BD MiniDraw™ Collection System in the future.Traditionally when a patient requires "blood work," a doctor orders the test, and an appointment is made at a laboratory service center where a nurse or phlebotomist draws tubes of blood from the patient's vein. The BD MiniDraw™ Collection System has the potential to transform this experience by expanding blood testing to new, more convenient settings, which can benefit patients, health care providers and collection sites. For patients, capillary collection with the BD MiniDraw™ Collection System provides the convenience of having blood drawn somewhere they already frequent, like a retail pharmacy or grocery store, which may have longer hours of operation and be closer to where they live or work. For these non-traditional collection sites, it enables expansion beyond existing health and wellness programs like administering vaccinations and can generate additional store traffic. For health care providers, capillary blood collection could be offered at a physician's office without the need for a phlebotomist. Making blood collection easier and less invasive may improve patient adherence to blood testing, for example, as part of annual wellness checks, which could lead to earlier diagnosis and better monitoring of chronic conditions. In May 2022, BD and Babson Diagnostics announced an expansion of their original strategic partnership agreement, announced in 2020, to advance development of the Babson BetterWay™ blood testing ecosystem, which includes the BD MiniDraw™ Collection System and Babson's proprietary automated sample-handling and analytical technologies. These were designed to work together to enable blood testing that requires only a fraction of the sample volume of traditional venipuncture methods without sacrificing quality or accuracy. Tillkännagivande • Nov 30
BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency BD launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines and other vascular access devices. The SiteRite™? 9 Ultrasound System is an all-in-one system designed with a user-friendly experience on an updated 15.6-inch touch screen with enhanced image quality that provides catheter placement tools and technologies to support clinicians during the vascular access device insertion process. The system includes integrated visualization tools such as the Cue™? Needle Tracking System to provide nurses with continuous and real-time needle tracking, and the Sherlock 3CG+™? Tip Confirmation System to ensure proper catheter tip navigation and location. SiteRite™? 9 also features smart, connected technology such as vessel assessment tools that automatically detect the vessel, then pair with vessel measurement tools to help clinicians select the appropriate catheter, so they can make an informed decision every time. Additional system capabilities include patient data look up with information capture, auto-filling capabilities and records transfer to help support clinician workflow. Tillkännagivande • Nov 23
Becton, Dickinson and Company Announces Executive Changes Becton, Dickinson and Company (BDX) named Ronald Silverman as executive vice president and chief medical officer, effective Dec. 4, 2023. Silverman succeeds William Sigmund, who had announced his wish to retire in June this year. Silverman was chief medical officer at 3M Health Care before joining BD. New Risk • Nov 14
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 30% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (19% operating cash flow to total debt). Minor Risk Large one-off items impacting financial results. Reported Earnings • Nov 14
Full year 2023 earnings released: EPS: US$5.14 (vs US$5.42 in FY 2022) Full year 2023 results: EPS: US$5.14 (down from US$5.42 in FY 2022). Revenue: US$19.4b (up 2.7% from FY 2022). Net income: US$1.47b (down 4.9% from FY 2022). Profit margin: 7.6% (down from 8.2% in FY 2022). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Europe. Tillkännagivande • Nov 12
Becton, Dickinson and Company Increases Quarterly Dividend, Payable on December 29, 2023 The Board of Directors of Becton, Dickinson and Company has declared a quarterly dividend of $0.95 per common share, an increase of 4.4% from the previous quarter. The dividend will be payable on December 29, 2023 to holders of record on December 8, 2023. The indicated annual dividend rate for fiscal year 2024 is $3.80 per share. Tillkännagivande • Nov 10
Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2024 Becton, Dickinson and Company provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the range of approximately $20.1 billion to $20.3 billion. Organic revenue growth is expected to be 5.25% to 6.25% including a headwind of over 25 basis points from the expected decline in COVID-only diagnostic testing. Total currency-neutral revenue growth is expected to be 4.5% to 5.5%. The company expects fiscal year 2024 adjusted diluted EPS to be $12.70 to $13.00, which represents growth of approximately 4% to 6.5%. Buying Opportunity • Nov 09
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be €278, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.6% over the last 3 years. Earnings per share has grown by 19%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings is also forecast to grow by 18% per annum over the same time period. Tillkännagivande • Nov 03
Becton, Dickinson and Company Announces Launch of Next-Generation Needle-Free Blood Draw Technology Becton, Dickinson and Company launched new needle-free blood draw technology compatible with integrated catheters, helping to further enable the company's vision of a "One-Stick Hospital Stay." With 510(k) clearance from the U.S. Food and Drug Administration (FDA), the new PIVO Pro Needle-free Blood Collection Device features design improvements to achieve the first and only compatibility with integrated and long peripheral IV catheters, including the new Nexiva Closed IV Catheter System with NearPort IV Access. This expands on current PIVO compatibility with traditional short peripheral IV catheters available since 2017. The new solution combines the clinical benefits shown for the integrated closed Nexiva Catheter System, including longer dwell times and reduced catheter complications, with the ability to draw high-quality blood samples directly from a patient's peripheral IV line with PIVO Pro, reducing the need for additional needlesticks. With needle phobia experienced by more than 60 percent of the adult population, this solution helps improve the patient experience by alleviating fear and anxiety associated with repetitive needlesticks. This new solution helps to reduce unnecessary and repeat needlesticks in the hospital while elevating clinical outcomes, improving workflow and creating a better experience for clinicians and patients." Peripheral IV insertion and blood collection are two of the most common in-patient procedures in hospitals touching almost every patient daily. These invasive procedures are associated with a variety of complications such as poor first-stick insertion success, frequent catheter failures and poor sample quality that can extend hospital stays, increase cost and create a dissatisfying experience. PIVO Pro combined with Nexiva with NearPort IV Access is designed to access optimal blood draw conditions and help improve clinician efficiency and patient experience. The innovative line draw solution has been shown to help optimize IV performance, reduce sample errors that can result in redraws and delays in patient care while reducing complications that lead to unnecessary procedures and IV replacements. By removing the needle from blood draws and reducing IV replacements, it may reduce the risk of needlestick injury and blood exposure for clinicians while preserving a patient's vessel health.(7,9,10) As the global leader in vascular access solutions, BD is committed to advancing the standard of care for IV therapy and blood draws for patients and health care providers. The latest innovation in the BD Peripheral Line Draw Solution further drives the BD "One-Stick Hospital Stay" vision across each of its three pillars _ including (1) helping to reduce unnecessary needlesticks by choosing the right vascular access device and placing it successfully the first time; (2) using one IV line as a single access point for required therapies and blood draws; and (3) optimal maintenance of the IV line to help reduce the risk of complications so it does not have to be replaced and lasts throughout a patient's hospital stay. Compared to open catheter system- Clinical studies were done on previous generations of the PIVO Blood Collection Device and Nexiva Catheter System. PIVO Pro and Nexiva with NearPort IV Access are the next generations of their respective product families. Tillkännagivande • Oct 18
BD Names Greg Rodetis as Senior Vice President of Investor Relations BD (Becton, Dickinson and Company) announced Greg Rodetis, currently BD senior vice president and treasurer will also add head of investor relations to his responsibilities, effective immediately. In this expanded role, Greg will continue as company treasurer and also lead all aspects of communicating progress of BD's strategy to investors and the financial community, including the company's initiatives that drive shareholder value. Rodetis will continue to report to Chris DelOrefice, executive vice president and chief financial officer for BD. Rodetis joined BD in 2016 as vice president and assistant treasurer, capital markets. In his current role as treasurer, Rodetis is responsible for leadership and oversight of the company's Treasury function as a strategic partner in supporting business performance, earnings growth and shareholder return. Prior to BD, Greg was with Terex Corporation as the assistant treasurer and prior to this he held roles of progressive responsibility with PepsiCo Inc., and General Electric Company. Rodetis holds a Bachelor of Science in Finance from Boston College and is a CFA® Charterholder. Tillkännagivande • Oct 13
Becton, Dickinson and Company to Report Q4, 2023 Results on Nov 09, 2023 Becton, Dickinson and Company announced that they will report Q4, 2023 results at 6:30 AM, US Eastern Standard Time on Nov 09, 2023 Buying Opportunity • Sep 29
Now 21% undervalued Over the last 90 days, the stock is up 1.7%. The fair value is estimated to be €309, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.6% over the last 3 years. Earnings per share has grown by 19%. For the next 3 years, revenue is forecast to grow by 5.0% per annum. Earnings is also forecast to grow by 18% per annum over the same time period. New Risk • Aug 04
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 22% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risk Large one-off items impacting financial results. Reported Earnings • Aug 03
Third quarter 2023 earnings released: EPS: US$1.37 (vs US$1.29 in 3Q 2022) Third quarter 2023 results: EPS: US$1.37 (up from US$1.29 in 3Q 2022). Revenue: US$4.88b (up 5.1% from 3Q 2022). Net income: US$392.0m (up 6.8% from 3Q 2022). Profit margin: 8.0% (up from 7.9% in 3Q 2022). Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Europe. Tillkännagivande • Jul 25
Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board On July 24, 2023, Dr. Joanne Waldstreicher was elected to the Board of Directors of Becton, Dickinson and Company (BD"). Upon joining BD's Board of Directors, Dr. Waldstreicher will serve as a member of both the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board. BD's Board of Directors has determined that Dr. Waldstreicher is independent under the rules of the New York Stock Exchange and the independence guidelines contained in BD's Statement of Corporate Governance Principles. Information regarding the compensation of the non-management members of BD's Board of Directors is included under the caption Non-Management Director Compensation" in BD's proxy statement relating to its 2023 Annual Meeting of Shareholders. Tillkännagivande • Jul 23
Becton, Dickinson and Company Receives FDA 510(k) Clearance for Updated BD Alaris™? Infusion System BD (Becton, Dickinson and Company) announced that the updated BD Alaris Infusion System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), which enables both remediation and a return to full commercial operations for the most comprehensive infusion system available in the United States. This clearance covers updated hardware features for Point-of-Care Unit (PCU), large volume pumps, syringe pumps, patient-controlled analgesia (PCA) pumps, respiratory monitoring and auto-identification modules. It also covers a new BD Alaris Infusion System software version with enhanced cybersecurity, along with interoperability features that enable smart, connected care with the most widely used electronic medical record (EMR) systems. Extending BD's Decades-Long Legacy of Leadership in Infusion Innovation: Today's clearance further enhances BD leadership in the infusion pump market. The updated BD Alaris Infusion system will help empower hospitals and health systems to optimize their workflows and deliver a higher standard of care, which has never been more important than in today's health care environment of staffing shortages and resource constraints. The BD Alaris Infusion System is the only system with a centralized user interface for up to four modules for all major types of infusions, including large volume pumps, syringe pump, and PCA therapy with optional respiratory monitoring. Having one, comprehensive infusion system enables hospitals and health systems to easily scale their infusion needs across an entire integrated delivery network and provide interoperability with EMR interoperability. With a common Point-of-Care Unit, one interface controls all modules, which is different from other pumps on the market that have non-modular architecture. The "one system" approach offers ease, simplicity and scalability. The BD Alaris infusion System also has the breadth of customers, the number of nurses trained on its use and the broadest experience and number of customers with EMR interoperability. Without this type of digital connectivity, clinicians are often required to navigate time-consuming processes, taking multiple steps to manually program infusions. The BD Alaris Inf Fusion System can also feed data to the BD HealthSight™? platform for enterprise medication management, which is a unique combination of connective technologies, analytics and expert services that turn information into insights among caregivers and create seamless visibility across BD medication management solutions. With this platform, health systems can view infusion status in real-time as well as access an intuitive knowledge portal with actionable information related to clinician trends and drug and fluid libraries. Tillkännagivande • Jul 07
Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023 Becton, Dickinson and Company announced that they will report Q3, 2023 results at 9:30 AM, US Eastern Standard Time on Aug 03, 2023 Tillkännagivande • Jun 21
STERIS Corporation agreed to acquire Surgical Instrumentation platform from Becton, Dickinson and Company for $540 million. STERIS Corporation entered into an agreement to acquire Surgical Instrumentation platform from Becton, Dickinson and Company for $540 million On June 15, 2023. The purchase price is subject to customary adjustments. STERIS Corporation will acquire the BD platform assets relating to surgical instrumentation, laparoscopic instrumentation and sterilization containers, including the V. Mueller, Snowden Pencer and Genesis branded products. The purchase price for the Transaction is $540 million in cash, subject to customary adjustments. STERIS is not assuming any debt and intends to fund the Transaction through a combination of debt and cash on hand. STERIS anticipates that the acquisition will qualify for a tax benefit related to tax deductible goodwill, with a present value of approximately $60 million. The Purchase Agreement also imposes customary confidentiality, non-solicitation and non-compete obligations upon the BD. The Purchase Agreement provides STERIS and the BD with certain termination rights. The completion of the Transaction is subject to the satisfaction or waiver of a number of customary conditions, including receipt of requisite Hart-Scott-Rodino Act approvals and Federal Trade Commission (FTC) regulatory approval. The divestiture will include V. Mueller™, Snowden-Pencer™ and Genesis™ branded products and three manufacturing facilities located in St.Louis, Cleveland, Ohio and Tuttlingen, Germany. Approximately 360 employees who support this platform will transfer to STERIS upon the completion of the transaction. Annual revenue for these businesses collectively for BD’s fiscal year ended September 30, 2023, is projected to be approximately $170 million, with adjusted earnings before interest and taxes of approximately $45 million. The divestiture is expected to close within BD's fiscal year 2023 ending, September 30, 2023. Marko Zatylny and Stephanie Lapidus of Ropes and Gray, LLP were legal advisers for Becton, Dickinson and Company (NYSE:BDX). Lazard & Co., Limited is serving as financial advisor to STERIS and Anthony E. Kuhel of Thompson Hine LLP is acting as legal counsel to STERIS Corporation. Reported Earnings • May 06
Second quarter 2023 earnings released Second quarter 2023 results: EPS: US$1.54. Net income: US$437.0m (up US$437.0m from 2Q 2022). Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Europe. Tillkännagivande • May 05
Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023 Becton, Dickinson and Company raised earnings guidance for the fiscal year 2023. For the year, the company expected revenues to be in the range of approximately $19.2 billion to $19.3 billion compared to $19.1 billion to $19.3 billion previously announced, which reflects an increase of approximately $50 million at the mid-point. Revenue guidance now assumes base business currency-neutral revenue growth of 6.5% to 7.0% compared to 5.75% to 6.75% previously announced, which represents an increase of 50 basis points, or approximately $90 million at the mid-point. Revenue guidance now assumes approximately $50 million in COVID-only diagnostic testing revenues, compared to approximately $50 million to $100 million previously announced. Based on current rates, foreign exchange continues to represent a reduction of approximately 200 basis points, or approximately $370 million, to total company revenue growth. Tillkännagivande • Feb 09
BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test BD announced that it has received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV) to help combat illness in the current and future respiratory virus seasons. The test, for use on the BD MAX Molecular Diagnostic System, uses a single nasal swab or a single nasopharyngeal swab sample to identify and distinguish if a patient has COVID-19, the flu, RSV or some combination of the three, with results available in as little as two hours. The test helps eliminate the need for multiple tests or doctor visits and can help clinicians implement the right treatment plan quickly. The co-testing approach also helps to increase testing capacity during the busy flu/RSV season and speed time to diagnosis. The BD MAX System is already in use at thousands of hospitals and laboratories worldwide, and each unit is capable of analyzing hundreds of samples over a 24-hour period. The Respiratory Viral Panel for BD MAX System is an RT- PCR assay that detects and differentiates the nucleic acid of SARS-CoV-2, flu A, flu B and RSV in as little as two hours for the first result, with the simplified and automated workflow of the BD MAX System. Development of this combination test has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority. The BD Respiratory Viral Panel assay for BD MAX System was CE marked under the IVD directive 98/79/EC in May of 2022. It is an important addition to the extensive number of assays available on the system across respiratory infections, sexually transmitted infections, gastrointestinal infections, women's health and health care associated infections. The BD MAX open system allows customers to leverage research use only (RUO) assays and user-defined protocols (UDP) to address emerging needs quickly. Tillkännagivande • Feb 04
Becton, Dickinson and Company Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery Becton, Dickinson and Company announced a new instrument for single-cell multiomics analysis that will enable scientists to run high-throughput studies without sacrificing sample integrity – potentially accelerating time to discovery across a wide range of disciplines including immunology, genetic disease research, and cancer and chronic disease research. The BD Rhapsody™ HT Xpress System enables scientists to isolate, barcode and analyze single cells at a high sample throughput — up to eight times more cells than prior versions of BD single-cell analyzers. The system ensures no sample loss and gives scientists the flexibility to analyze multiple samples and different cell sizes and types, such as stem cells or cancer cells, at the same time, to obtain more insights in less time. The new technology will be on display at the Advances in Genome Biology and Technology (AGBT) General Meeting February 6-9 in Hollywood, Florida. Single-cell multiomics is a rapidly growing approach that enables researchers to look at multiple layers of "omics" (including genomics, transcriptomics, proteomics and metabolomics) information on a single cell, to exponentially increase the parameters that can be investigated and uncover a more comprehensive view of health and disease. Additionally at the AGBT General Meeting, BD will introduce the BD Rhapsody™ Mouse TCR/BCR Multiomic Assay, a cell receptor profiling tool for single-cell studies, as well as BD® Flex Single-Cell Multiplexing Kits, a companion tool for single-cell studies on any BD Rhapsody system, including the BD Rhapsody™ HT Xpress System, enabling more elements to be measured in a single run by expanding the number of sample tags. BD will also present data on these latest innovations. BD is completing early-access testing for the BD Rhapsody™ HT Xpress System, which will soon be commercially available globally. Reported Earnings • Feb 04
First quarter 2023 earnings released: EPS: US$1.71 (vs US$2.30 in 1Q 2022) First quarter 2023 results: EPS: US$1.71 (down from US$2.30 in 1Q 2022). Revenue: US$4.59b (down 8.2% from 1Q 2022). Net income: US$486.0m (down 26% from 1Q 2022). Profit margin: 11% (down from 13% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Europe. Tillkännagivande • Feb 03
Becton, Dickinson and Company Provides Earnings Guidance for the Year 2023 Becton, Dickinson and Company provided earnings guidance for the year 2023. For the year, the company expects fiscal year 2023 revenues to be in the range of approximately $19.1 billion to $19.3 billion compared to $18.6 billion to $18.8 billion previously announced, which reflects an increase of approximately $500 million at the mid-point. Tillkännagivande • Jan 25
BD (Becton, Dickinson and Company) Declares Quarterly Dividend, Payable on March 31, 2023 The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.91 per common share, payable on March 31, 2023 to holders of record on March 10, 2023. The indicated annual dividend rate is $3.64 per share. Tillkännagivande • Jan 12
Becton, Dickinson and Company Introduces Fully Automated Robotic Track System for Microbiology Labs Becton, Dickinson and Company introduced a new, robotic track system for the BD Kiestra™ microbiology laboratory solution that automates lab specimen processing, which may help to reduce manual labor and wait time for results. The new BD Kiestra™ 3rd Generation Total Lab Automation System allows laboratories to create a custom and flexible total lab automation configuration to connect multiple BD Kiestra™ modules and is scalable to meet labs' unique and evolving needs. With multiple track options and choice of instruments to employ, labs can choose their automation entry point and configure the system to fit their individual workflow and physical lab space. From routine specimen inoculation processes to advanced incubation, imaging and colony selection for pathogen identification, the workflow can be fully automated and is customizable to fit the physical lab space. In addition, each step of the lab's diagnostic pathway is traceable and powered by BD Synapsys™ informatics solution to enable integrated workflows and on-demand insights that help empower laboratory staff to impact turnaround time, expedite laboratory decision-making, improve productivity, and support their compliance requirements. Tillkännagivande • Jan 10
Becton, Dickinson and Company and CerTest Biotec Announce Emergency Use Authorization from U.S. Food and Drug Administration for Molecular Polymerase Chain Reaction Assay for Mpox Virus Detection Becton, Dickinson and Company and CerTest Biotec have announced Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a molecular polymerase chain reaction (PCR) assay for Mpox virus detection. The VIASURE Monkeypox Virus Real Time PCR Reagents for BD MAX System is now available for BD MAX™ System users. The BD MAX™ System is a fully integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in less than three hours. BD offers an extensive menu of tests on the system covering health care associated infections, respiratory infections, sexually transmitted infections, gastrointestinal infections and women's health. As with all CerTest assays, the VIASURE Monkeypox Virus PCR Detection assay for the BD MAX™ System is offered in a lyophilized format. Accordingly, the assay will come in a tube that snaps into the test-specific position on the BD MAX™ ExK™ TNA extraction strip, which is supplied by BD. Tillkännagivande • Jan 07
Becton, Dickinson and Company Announces Executive Changes Becton, Dickinson and Company announced that Michelle Quinn has been named acting general counsel of BD, succeeding Samrat (Sam) Khichi, who has informed the company of his intent to depart BD for a new opportunity, effective Feb. 3, 2023. Quinn, 54, will be responsible for leading the Law Group at BD. She will report to Tom Polen, chairman, CEO and president of BD and become a member of the BD Executive Leadership Team. Quinn joined BD in 2019 and currently serves as senior vice president, deputy general counsel, and chief ethics andcompliance officer. Before joining BD, she was vice president and general counsel of North America for Sandoz Inc. and prior to that served as vice president and associate general counsel at Catalent Pharma Solutions. Quinn holds a Juris Doctor from Villanova University and a Bachelor of Arts in Political Science from Colgate University. As part of the leadership transition, BD also announced that effective February 3, Ami Simunovich, executive vice president and chief regulatory officer, will report directly to Polen and Public Affairs will report to Simunovich. Inaddition, Corporate Development will report to Chris DelOrefice, executive vice president and chief financial officer, bringing a closer alignment between Corporate Development and Corporate Strategy. Khichi, 55, is currently general counsel and executive vice president, Corporate Development, Public Affairs andRegulatory Affairs, which he has served as since 2017, when he joined BD through the acquisition of C. R. Bard. Prior to joining BD, Khichi was senior vice president, general counsel and secretary at C. R. Bard. Prior to Bard, he served as senior vice president, chief administrative officer and general counsel for Catalent Pharma Solutions. Tillkännagivande • Jan 06
Becton, Dickinson and Company to Report Q1, 2023 Results on Feb 02, 2023 Becton, Dickinson and Company announced that they will report Q1, 2023 results at 6:30 AM, US Eastern Standard Time on Feb 02, 2023 Tillkännagivande • Dec 21
Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023 Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023, at 13:00 US Eastern Standard Time. Location: The Biltmore Hotel Miami Coral Gables, 1200 Anastasia Ave, Coral Gables, Florida Florida United States Agenda: To elect as directors of the eleven nominees names attached in the proxy statement doe one year term; to consider the ratification of selection of independent registered public accounting firm; to consider the advisory vote to approve named executive officer compensation; and to discuss other related matters. Buying Opportunity • Dec 03
Now 20% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be €298, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.9% over the last 3 years. Earnings per share has grown by 28%. For the next 3 years, revenue is forecast to grow by 4.1% per annum. Earnings is also forecast to grow by 16% per annum over the same time period. Reported Earnings • Nov 24
Full year 2022 earnings released: EPS: US$5.42 (vs US$5.23 in FY 2021) Full year 2022 results: EPS: US$5.42 (up from US$5.23 in FY 2021). Revenue: US$18.9b (down 1.4% from FY 2021). Net income: US$1.55b (up 2.0% from FY 2021). Profit margin: 8.2% (up from 7.9% in FY 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Medical Equipment industry in Europe. 
